
TORONTO, Sept. 27 /CNW/ - Patheon Inc. (TSX: PTI) today announced that the Warning Letter received by its subsidiary, CEPH International Corporation (CEPH), from the San Juan, Puerto Rico District office of the U.S. Food and Drug Administration, (FDA) on September 16, 2005 has been posted on the FDA's website at www.fda.gov. As indicated in the Warning Letter, the affected product is powder for oral suspension, Omnicef OP 250 mg/5mL and 125 mg/5mL. The issues identified in the Warning Letter affect all manufacturing lines for the powder for oral suspension product. The capsule product is not affected. Patheon and CEPH are working diligently with their client to resolve the issues identified by the FDA in the Warning Letter. CEPH has decided to voluntarily suspend production of the powder product while it resolves these matters. Patheon and CEPH are committed to working expeditiously to resolve these issues so as to avoid interruption of supply of the product for the client. Patheon (TSX: PTI; www.patheon.com) is a leading global provider of drug development and manufacturing services to the international pharmaceutical industry. With the addition of its wholly owned subsidiary MOVA Pharmaceutical Corporation, acquired in December 2004, Patheon operates a network of 14 facilities in the United States, Canada and Europe, employing more than 5,900 people and serving a client base of 180 pharmaceutical and biotechnology companies. %SEDAR: 00001700E